

0300



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Collinson et al.
 Serial No.: 09/894,550
 Filed: 28 June 2001
 Entitled: DUAL SPECIFICITY ANTIBODIES
 AND METHODS OF MAKING
 AND USING

ART UNIT: 1645
 EXAMINER: (not yet assigned)

Attorney Docket No.: BBC-083A US

*Asst. Commissioner for Patents
 US Patent and Trademark Office
 Box Sequence
 P.O. Box 2327
 Arlington, VA 22202*

TRANSMITTAL LETTER and REQUEST FOR EXTENSION OF TIME

Sir/Madam:

Transmitted herewith are: [X] a Preliminary Amendment; [X] a Sequence Listing paper copy (3 sheets); [X] a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures; [X] a Computer Readable Form of the Sequence Listing; [X] a statement of Sequence Listing content; and [X] a return postcard, for filing in the above-identified patent application.

FEE FOR ADDITIONAL CLAIMS


- [X] A fee for additional claims is not required.
 [] A fee for additional claims is required. The additional fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER OF EXCESS CLAIMS	RATE	FEES DUE
TOTAL CLAIMS	88	88	0	× \$18	= 0.00
INDEPENDENT	6	6	0	× \$84	= 0.00
FIRST INTRODUCTION OF MULT. DEPENDENT CLAIM				+\$280	= 0.00
TOTAL FEES DUE					= 00.00

PETITION FOR EXTENSION OF TIME

- [] Extension is requested under 37 CFR 1.136(a), and the following extension fee is applicable for the paper(s) filed herewith: [] \$110.00 for response within first month pursuant to 37 CFR 1.17(a)(1);
[] \$400.00 for response within second month pursuant to 37 CFR 1.17(a)(2);
[] \$920.00 for response within third month pursuant to 37 CFR 1.17(a)(3);
[] \$1,440.00 for response within fourth month pursuant to 37 CFR 1.17(a)(4);
[] \$1,960.00 for response within fifth month pursuant to 37 CFR 1.17(a)(5);
- [X] **The Commissioner is hereby authorized to charge payment of any fees required in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 01 0025. A duplicate copy of this transmittal letter is transmitted herewith.**

Respectfully submitted,




Kenneth P. Zwicker, PhD
Registration No. 43,310
Attorney for Applicants

CERTIFICATE OF MAILING

The undersigned hereby certifies this correspondence is being deposited with the U.S. Postal Service as First Class Mail, postage prepaid, in an envelope addressed to the Asst. Commissioner for Patents, US Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202 on the date indicated below

16 MAY 2002

Date of mailing and signature



Angela Perno



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Collinson et al.

Serial No.: 09/894,550

Filed: 28 June 2001

Entitled: DUAL SPECIFICITY ANTIBODIES
AND METHODS OF MAKING
AND USING

ART UNIT: 1645

EXAMINER: (not yet assigned)

Attorney Docket No.: BBC-083A US

*Asst. Commissioner for Patents
US Patent and Trademark Office
Box Sequence
P.O. Box 2327
Arlington, VA 22202*

**Transmittal of Sequence Listing, Computer Readable Form, and Amendment
pertaining thereto for invention containing nucleotide and/or amino acid sequence disclosure
under 37 C.F.R. §§1.821-1.825**

Sir/Madam:

Please find enclosed; a paper copy Sequence Listing (3 pages), a diskette containing a computer readable form (CRF) copy of the Sequence Listing, and an amendment for the above-referenced patent application.

Applicants have assigned a separate identifier to each of the 4 sequences disclosed, as required under 37 C.F.R. §§1.821-1.825.


Applicants verify the following:

1. The enclosed sequence listing information recorded in the computer readable form is identical to the written paper copy Sequence Listing for the above-identified patent application, as required under 37 CFR §1.821(f);
2. The written paper copy Sequence Listing and the enclosed computer readable form of the Sequence Listing for the above-identified patent application contain no new matter

and do not go beyond the original disclosure of the application, as required under 37 CFR §1.821(g);

3. The Sequence Listing and the enclosed computer readable form of the Sequence Listing for the above-identified patent application are in a form and format in accordance with 37 CFR §§1.822, 1.823, and 1.824.

Respectfully submitted,




Kenneth P. Zwicker, PhD
Registration No. 43,310
Attorney for Applicants

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail, postage prepaid, in an envelope addressed to the Asst. Commissioner for Patents, US Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202 on the date indicated below.

16 MAY 2003
Date of mailing and signature


Angela Perno